Novavax, Inc. (NVAX)
| Market Cap | 1.84B |
| Revenue (ttm) | 996.61M |
| Net Income (ttm) | -398.71M |
| Shares Out | 140.40M |
| EPS (ttm) | -3.13 |
| PE Ratio | n/a |
| Forward PE | 1.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,243,638 |
| Open | 14.35 |
| Previous Close | 14.40 |
| Day's Range | 12.95 - 14.38 |
| 52-Week Range | 3.53 - 15.00 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 14.00 (+7.61%) |
| Earnings Date | May 10, 2024 |
About NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n... [Read more]
Financial Performance
In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 7.61% from the latest price.
News
Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?
The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in ...
Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem...
Novavax to Participate in BofA Securities 2024 Health Care Conference
GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal
Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi...
Novavax (NVAX) Deal with Sanofi to Co-Commercialize Covid Vaccine
Novavax (NVAX) signed a deal with drugmaker Sanofi to co-commercialize the Covid Vaccine. Diane King Hall discusses this, as well as Novavax's 1Q earnings.
Novavax stock soars on $1.2 billion Sanofi vaccine deal
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brie...
Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines
Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).
Novavax Shares Surge Over 140% After $1.4 Billion Covid Shot Deal With Sanofi
Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...
Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.
The two companies will also work on a shot that combines Covid-19 and flu vaccines.
Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal wi...
Novavax shares surge on new $1.4 billion deal with Sanofi
Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influen...
Novavax erases doubts about its ability to remain in business
COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice.
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's...
France's Sanofi in COVID-19 vaccine deal with Novavax - statement
Sanofi on Friday announced it has reached a 'co-exclusive' licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines.
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equ...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024
GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first qu...
Novavax's top shareholder Shah Capital ramps up efforts for board shakeup
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shak...
Hedge fund Shah Capital recommends two new candidates for Novavax board
U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax board.
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
Hedge fund Shah Capital on Monday called for an “urgent shake up” at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccines to boost sale...
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data ...
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD...
Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year'
Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.